GlassScriptPhysician profile
Jamal A Abusuwa
NPI 1053310342
$2,205.46
in general payments reported to CMS, 2019-2025
26 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $448 · 2021: $312 · 2022: $436 · 2023: $469 · 2024: $89.66 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $348.77 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $253.38 | 2021-2024 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $252.15 | 2019-2023 | Emgality, Jardiance, Mounjaro |
| Amarin Pharma, INC. | $252.09 | 2020-2022 | |
| Pfizer INC. | $186.77 | 2020-2023 | |
| Novo Nordisk INC | $160.53 | 2020-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.19 | 2019-2023 | Jardiance, Synjardy |
| Amgen INC. | $109.96 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.84 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $65.66 | 2020-2021 | |
| Glaxosmithkline, LLC. | $57.45 | 2019-2021 | |
| Exact Sciences Corporation | $49.19 | 2024-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $46.06 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.20 | 2019 | |
| Paratek Pharmaceuticals, INC. | $19.67 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19.08 | 2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $18.65 | 2023 | Xarelto |
| Medtronic, INC. | $17.91 | 2025 | Inceptiv |
| Inspire Medical Systems, INC. | $17.37 | 2025 | Inspire |
| Sanofi Pasteur INC. | $17.10 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.73 | 2024 | Voquezna |
| Phadia US INC. | $13.14 | 2023 | Immunocap |
| Gilead Sciences, INC. | $13.07 | 2023 | |
| Novartis Pharmaceuticals Corporation | $13.01 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.30 | 2019 | |
| Allergan, INC. | $11.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamal Abusuwa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.